ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 61 filers reported holding ALIGOS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,733,325 | -23.1% | 2,320,381 | 0.0% | 0.92% | -65.5% |
| Q2 2023 | $2,253,090 | +11.1% | 2,320,381 | 0.0% | 2.67% | -36.8% |
| Q1 2023 | $2,028,013 | -8.3% | 2,320,381 | 0.0% | 4.23% | -7.6% |
| Q4 2022 | $2,211,091 | -13.4% | 2,320,381 | 0.0% | 4.58% | +5.1% |
| Q3 2022 | $2,552,000 | -9.1% | 2,320,381 | 0.0% | 4.35% | +1.1% |
| Q2 2022 | $2,808,000 | -43.7% | 2,320,381 | 0.0% | 4.30% | -13.6% |
| Q1 2022 | $4,989,000 | -81.9% | 2,320,381 | 0.0% | 4.98% | -66.2% |
| Q4 2021 | $27,543,000 | -23.5% | 2,320,381 | 0.0% | 14.73% | -1.1% |
| Q3 2021 | $35,989,000 | -23.9% | 2,320,381 | 0.0% | 14.90% | -4.9% |
| Q2 2021 | $47,301,000 | -36.8% | 2,320,381 | -29.5% | 15.67% | +7.4% |
| Q1 2021 | $74,868,000 | -17.8% | 3,292,339 | 0.0% | 14.59% | +54.3% |
| Q4 2020 | $91,033,000 | – | 3,292,339 | – | 9.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $1,733,325 | 0.92% |
| TANG CAPITAL MANAGEMENT LLC | 3,329,048 | $2,486,799 | 0.35% |
| Vivo Capital, LLC | 3,547,030 | $2,649,631 | 0.29% |
| Pivotal bioVenture Partners Investment Advisor LLC | 743,215 | $555,182 | 0.22% |
| Newtyn Management, LLC | 920,000 | $687,240 | 0.17% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 631,887 | $472,020 | 0.14% |
| EcoR1 Capital, LLC | 3,948,360 | $2,949,425 | 0.10% |
| HHLR ADVISORS, LTD. | 2,309,764 | $1,725,394 | 0.04% |
| Baker Brothers Advisors | 2,076,400 | $1,551,071 | 0.01% |
| HARBOURVEST PARTNERS LLC | 18,783 | $14,031 | 0.01% |